102 related articles for article (PubMed ID: 22023247)
1. Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: a hypothesis.
Wostyn P; van Dam D; Audenaert K; de Deyn PP
J Neurogenet; 2011 Dec; 25(4):195-200. PubMed ID: 22023247
[TBL] [Abstract][Full Text] [Related]
2. Can chronic increased intracranial pressure or exposure to repetitive intermittent intracranial pressure elevations raise your risk for Alzheimer's disease?
Wostyn P
Med Hypotheses; 2004; 62(6):925-30. PubMed ID: 15142650
[TBL] [Abstract][Full Text] [Related]
3. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.
Nakamura T; Shoji M; Harigaya Y; Watanabe M; Hosoda K; Cheung TT; Shaffer LM; Golde TE; Younkin LH; Younkin SG
Ann Neurol; 1994 Dec; 36(6):903-11. PubMed ID: 7998778
[TBL] [Abstract][Full Text] [Related]
4. A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease.
Serot JM; Zmudka J; Jouanny P
J Alzheimers Dis; 2012; 30(1):17-26. PubMed ID: 22349684
[TBL] [Abstract][Full Text] [Related]
5. Disruption of cerebrospinal fluid flow through the olfactory system may contribute to Alzheimer's disease pathogenesis.
Ethell DW
J Alzheimers Dis; 2014; 41(4):1021-30. PubMed ID: 24769627
[TBL] [Abstract][Full Text] [Related]
6. Impairments in brain-to-blood transport of amyloid-β and reabsorption of cerebrospinal fluid in an animal model of Alzheimer's disease are reversed by antisense directed against amyloid-β protein precursor.
Banks WA; Kumar VB; Farr SA; Nakaoke R; Robinson SM; Morley JE
J Alzheimers Dis; 2011; 23(4):599-605. PubMed ID: 21098986
[TBL] [Abstract][Full Text] [Related]
7. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation.
Kauwe JS; Jacquart S; Chakraverty S; Wang J; Mayo K; Fagan AM; Holtzman DM; Morris JC; Goate AM
Ann Neurol; 2007 May; 61(5):446-53. PubMed ID: 17366635
[TBL] [Abstract][Full Text] [Related]
8. [Genetic factors and a polygenic model of Alzheimer's disease].
Rogaev EI
Genetika; 1999 Nov; 35(11):1558-71. PubMed ID: 10624576
[TBL] [Abstract][Full Text] [Related]
9. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
[TBL] [Abstract][Full Text] [Related]
10. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
Xu BG; Wu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
[TBL] [Abstract][Full Text] [Related]
11. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro.
Ono K; Noguchi M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M
Neurobiol Dis; 2005 Nov; 20(2):233-40. PubMed ID: 16242632
[TBL] [Abstract][Full Text] [Related]
13. [Genetics of late-onset Alzheimer's disease: vascular risk and beta-amyloid metabolism].
Panza F; Solfrizzi V; D'Introno A; Capurso C; Colacicco AM; Torres F; Altomare E; Capurso A
Recenti Prog Med; 2002 Sep; 93(9):489-97. PubMed ID: 12355988
[TBL] [Abstract][Full Text] [Related]
14. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
15. [Genes in Alzheimer's disease].
Hoenicka J
Rev Neurol; 2006 Mar 1-15; 42(5):302-5. PubMed ID: 16538594
[TBL] [Abstract][Full Text] [Related]
16. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
Hansson SF; Andréasson U; Wall M; Skoog I; Andreasen N; Wallin A; Zetterberg H; Blennow K
J Alzheimers Dis; 2009; 16(2):389-97. PubMed ID: 19221428
[TBL] [Abstract][Full Text] [Related]
17. Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features.
Giaccone G; Morbin M; Moda F; Botta M; Mazzoleni G; Uggetti A; Catania M; Moro ML; Redaelli V; Spagnoli A; Rossi RS; Salmona M; Di Fede G; Tagliavini F
Acta Neuropathol; 2010 Dec; 120(6):803-12. PubMed ID: 20842367
[TBL] [Abstract][Full Text] [Related]
18. Age-related changes in brain extracellular space affect processing of amyloid-β peptides in Alzheimer's disease.
Bondareff W
J Alzheimers Dis; 2013; 35(1):1-6. PubMed ID: 23364138
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology.
Maddalena AS; Papassotiropoulos A; Gonzalez-Agosti C; Signorell A; Hegi T; Pasch T; Nitsch RM; Hock C
Neurodegener Dis; 2004; 1(4-5):231-5. PubMed ID: 16908995
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization.
Ikeda T; Ono K; Elashoff D; Condron MM; Noguchi-Shinohara M; Yoshita M; Teplow DB; Yamada M
J Alzheimers Dis; 2010; 21(1):81-6. PubMed ID: 20413863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
